NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices
This article was originally published in The Tan Sheet
Executive Summary
FDA is planning a prospective study on the root causes of multiple-cycle drug and biologic reviews as part of an effort to improve the review process, Commissioner Mark McClellan, MD/PhD, announced Jan. 31